Ming Lu

5.1k total citations
140 papers, 3.0k citations indexed

About

Ming Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ming Lu has authored 140 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 45 papers in Surgery. Recurrent topics in Ming Lu's work include Gastric Cancer Management and Outcomes (36 papers), Lung Cancer Research Studies (29 papers) and Neuroendocrine Tumor Research Advances (26 papers). Ming Lu is often cited by papers focused on Gastric Cancer Management and Outcomes (36 papers), Lung Cancer Research Studies (29 papers) and Neuroendocrine Tumor Research Advances (26 papers). Ming Lu collaborates with scholars based in China, Ethiopia and United States. Ming Lu's co-authors include Lin Shen, Jifang Gong, Jun Zhou, Zhihao Lü, Xicheng Wang, Zhi Peng, Jing Gao, Xiaotian Zhang, Jian Li and Lin Shen and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ming Lu

129 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ming Lu China	28	1.4k	951	733	701	510	140	3.0k
Motohiro Imano Japan	32	856 0.6×	890 0.9×	913 1.2×	1.1k 1.5×	247 0.5×	164	3.1k
Harold Frucht United States	30	1.6k 1.2×	754 0.8×	454 0.6×	1.2k 1.7×	927 1.8×	61	3.2k
Qiwen Ben China	27	1.7k 1.2×	894 0.9×	451 0.6×	1.2k 1.7×	694 1.4×	47	3.1k
Izumi Takeyoshi Japan	35	979 0.7×	1.5k 1.6×	1.0k 1.4×	1.3k 1.8×	369 0.7×	341	4.4k
Janete M. Cerutti Brazil	32	687 0.5×	773 0.8×	210 0.3×	1.3k 1.9×	414 0.8×	102	3.7k
Misa Nakamura Japan	30	1.0k 0.7×	479 0.5×	305 0.4×	1.3k 1.9×	233 0.5×	146	3.0k
Guido Eibl United States	39	2.0k 1.4×	1.2k 1.3×	436 0.6×	1.8k 2.5×	458 0.9×	102	4.1k
Bei Zhang China	26	942 0.7×	357 0.4×	464 0.6×	682 1.0×	310 0.6×	191	2.4k
Yuji Morine Japan	34	1.3k 0.9×	1.7k 1.8×	726 1.0×	1.2k 1.7×	749 1.5×	272	4.4k
Shingo Tsuji Japan	26	519 0.4×	509 0.5×	369 0.5×	1.1k 1.5×	460 0.9×	78	2.7k

Countries citing papers authored by Ming Lu

Since Specialization

Citations

This map shows the geographic impact of Ming Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming Lu more than expected).

Fields of papers citing papers by Ming Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming Lu. The network helps show where Ming Lu may publish in the future.

Co-authorship network of co-authors of Ming Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Ming Lu. A scholar is included among the top collaborators of Ming Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming Lu. Ming Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Ying, Panpan Zhang, Ming Lu, et al.. (2025). Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunology Immunotherapy. 74(3). 83–83.

Zhang, Xuezhi, et al.. (2025). Association Between Serum Ferritin and In-hospital Mortality in Critical Ills with Sepsis-Associated Acute Kidney Injury: A Retrospective Cohort Study. 8(1). p58–p58. 1 indexed citations

Li, Yumei, et al.. (2024). The synergistic impact of socioeconomic and landscape factors on spatial patterns of human-wildlife conflicts. Biological Conservation. 290. 110431–110431. 3 indexed citations

Ma, Xiaofan, Xiaoyu Hu, Kai Liu, et al.. (2024). Spatiotemporal differences induced changes in the structure and function of the gut microbiota in an endangered ungulate. SHILAP Revista de lepidopterología. 6(1). 74–74. 2 indexed citations

Li, Yumei, et al.. (2024). Effects of expansion of protected areas and habitat transformation on spatiotemporal variation in human–wildlife conflict. Conservation Biology. 39(2). e14393–e14393. 2 indexed citations

Wang, Yakun, Jifang Gong, Airong Wang, et al.. (2024). Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 68. 102415–102415. 40 indexed citations

Zhang, Qi, Ye Zhou, Lijie Song, et al.. (2023). China special issue on gastrointestinal tumors‐Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study. International Journal of Cancer. 153(11). 1885–1893. 4 indexed citations

Jiang, Kai, Fang Cao, Lianghong Yin, et al.. (2023). Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study. Journal of Endocrinological Investigation. 47(5). 1251–1260.

Liu, Yang, Wenfei Li, Zhihao Lü, et al.. (2022). Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. BMC Cancer. 22(1). 355–355. 4 indexed citations

10.

Xie, Tong, Qin Feng, Zhongwu Li, et al.. (2021). Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review. Hereditary Cancer in Clinical Practice. 19(1). 7–7. 7 indexed citations

11.

Lu, Ming, Xianjun Yu, Zewen Chen, et al.. (2021). 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study. Annals of Oncology. 32. S1448–S1448.

12.

Peng, Zhi, Siyuan Cheng, Yan Kou, et al.. (2020). The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunology Research. 8(10). 1251–1261. 235 indexed citations

13.

Cao, Yanshuo, Yutong Ma, Jiangyuan Yu, et al.. (2020). Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide‐induced high tumor mutational burden. Cancer Communications. 40(12). 746–751. 19 indexed citations

14.

Zhang, Zhening, Siyuan Cheng, Jifang Gong, et al.. (2020). Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series. European Journal of Surgical Oncology. 46(10). e33–e39. 26 indexed citations

15.

Wen, Lei, Zhaoming Zhou, Tao Lin, et al.. (2020). Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study. Radiation Oncology. 15(1). 185–185. 21 indexed citations

16.

Wang, Yakun, Li Sun, Zhongwu Li, et al.. (2019). Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer. 22(6). 1183–1192. 62 indexed citations

17.

Zhang, Qiyue, Fei Shan, Ziyu Li, et al.. (2018). A prospective study on the changes and clinical significance of pre-operative and post-operative circulating tumor cells in resectable gastric cancer. Journal of Translational Medicine. 16(1). 171–171. 30 indexed citations

18.

Larsson, Catharina, Jamileh Hashemi, Jorge Barriuso, et al.. (2016). Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. 101(10). 3616–3627. 10 indexed citations

19.

Peng, Zhi, Zhongwu Li, Jing Gao, et al.. (2015). Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 14(11). 2634–2641. 19 indexed citations

20.

Guo, Xiang, Bin Ni, Ning Xie, et al.. (2014). Bilateral C1–C2 Transarticular Screw and C1 Laminar Hook Fixation and Bone Graft Fusion for Reducible Atlantoaxial Dislocation: A Seven-Year Analysis of Outcome. PLoS ONE. 9(1). e87676–e87676. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact